PQB.STU Pure Biologics Spólka Akcyjna

Healthcare Biotechnology Stuttgart Exchange
0.2450 EUR
Close of Oct 31, 2026
0.0500 1.23
Market cap
EUR 55.3M
P/E
-
P/B
1.52x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PQB.STU undervalued?

Graham number

The Graham number of Pure Biologics Spólka Akcyjna cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pure Biologics Spólka Akcyjna fundamental analysis

No fundamental analysis for Pure Biologics Spólka Akcyjna yet.

Pure Biologics Spólka Akcyjna stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pure Biologics Spólka Akcyjna

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offe…

Full company profile